GenMark, T2 And Accelerate Diagnostics Impress Analysts At Microbiology Forum

Canaccord Genuity provided some remarks on three companies after attending the "American Society for Microbiology" forum. According to the report published Monday, the Canaccord Genuity analysts are positive on GenMark Diagnostics, Inc GNMK and T2 Biosystems Inc TTOO, and they expect Accelerate Diagnostics Inc AXDX to remain a key player to follow in 2016–2017.

Related Link: NantHealth Uses The Cloud To Offer Value, Drive Earnings

The analysts noted it is possible to see "additional consolidation as upstart growth companies enter new verticals, or eat into the shares of the incumbents," despite a strong competition in infectious disease. Strong traffic was noticed in booths of all three companies during the exhibition.

At Time Of Writing...

• Accelerate was down 4.41 percent at $14.30 on the day.
• T2 was down 2.47 percent at $8.29.
• GenMark was down 3.95 percent at $8.02.